baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Regeneron Pharmaceuticals/ US75886F1075 /

2024-04-29 9:59:58 PM	Chg. -	Volume	Bid1:14:44 PM	Ask10:25:01 PM	Market Capitalization	Dividend Y.	P/E Ratio
893.74USD	-	20,981 Turnover: 6.29 mill.	-Bid Size: -	-Ask Size: -	97.96 bill.USD	-	24.09

GlobeNewswire 04-29 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...

GlobeNewswire 04-26 Medigene AG reports Financial Results and Business Update for Q1 2024

GlobeNewswire 04-25 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...

GlobeNewswire 04-24 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...

GlobeNewswire 04-23 Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire 04-22 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...

GlobeNewswire 04-18 Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals,...

GlobeNewswire 04-18 REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Beh...

GlobeNewswire 04-16 Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

GlobeNewswire 04-16 Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

GlobeNewswire 04-15 Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation

GlobeNewswire 04-11 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Phar...

GlobeNewswire 04-09 Opthea Appoints John Han, PharmD, as VP Medical Affairs

GlobeNewswire 04-07 Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in ...

GlobeNewswire 04-01 Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and ...

GlobeNewswire 03-25 Regeneron Provides Update on Biologics License Application for Odronextamab

GlobeNewswire 03-22 Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm

GlobeNewswire 03-20 Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

GlobeNewswire 03-18 CIO Celebrates Innovations in Business Technology with 2024 CIO 100 & Hall of Fame Awards

GlobeNewswire 03-13 High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientif...

GlobeNewswire 03-11 Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High C...

GlobeNewswire 03-08 EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) a...

GlobeNewswire 02-28 Opthea Reports Half-Year Financial Results and Business Updates

GlobeNewswire 02-28 Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portf...

GlobeNewswire 02-23 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflam...

Regeneron Pharmaceuticals/ US75886F1075 /

If you wish to receive reply to your feedback, please provide your email address.